Latest Nerve Repair News

Page 1 of 7
ReNerve has converted Indian regulatory approval into its first commercial NervAlign Nerve Cuff procedure, with a Bangalore patient treated for an upper-extremity nerve repair. The milestone arrives after record quarterly sales of $584,000 and expands the company’s Asia-Pacific rollout.
Victor Sage
Victor Sage
17 Nov 2026
Orthocell has recorded its strongest month of US Remplir sales since launch, with 92 units generating A$279,000 in October. The result points to improving surgeon adoption and hospital access, although one month of sales does not yet establish a durable run rate or profitability.
Victor Sage
Victor Sage
2 Nov 2026
ReNerve has reported its strongest quarter yet, with sales climbing to $584,000 as the medical device company expands across Asia-Pacific. The growth came alongside a secured funding drawdown, leaving the company with $1.62 million in cash but continued negative operating cash flow.
Victor Sage
Victor Sage
26 Oct 2026
Orthocell’s flagship Remplir nerve-repair product gained ground in the US and Thailand during the September quarter, even as total revenue slipped from the June period. The company reported A$39 million in available funds and said it does not currently expect to raise additional capital.
Ada Torres
Ada Torres
22 Oct 2026
Orthocell says Remplir was placed successfully in five complex robotic prostatectomy cases, with no device-related complications reported over approximately 12 months. The preliminary results will guide a larger prospective trial ahead of a planned US expansion for the nerve repair product.
Ada Torres
Ada Torres
13 Oct 2026
ReNerve’s October AGM presentation points to sharply higher sales, a growing US distribution network and a broader nerve repair pipeline. The company is also progressing a 240-patient NervAlign clinical study while relying on a $5 million RiverFort funding facility to support expansion.
Victor Sage
Victor Sage
5 Oct 2026
Orthocell has recorded the first commercial sales of its Remplir nerve repair product in Thailand, opening a new market estimated at US$84 million. The launch gives the company another distributor-led growth channel, although near-term sales are expected to remain modest.
Ada Torres
Ada Torres
21 Sept 2026
Orthocell posts record FY26 revenue growth driven by expanding US and international sales of its collagen medical devices, while investing ahead in manufacturing capacity and product pipeline.
Ada Torres
Ada Torres
31 Aug 2026
ReNerve Ltd (ASX:RNV) reported an 80% year-on-year revenue increase in Q4 FY26, backed by expanding product lines and a $5 million funding facility. The company is advancing FDA approvals and growing its global distribution footprint, targeting a rapidly expanding $6.19 billion nerve repair biomaterials market.
Ada Torres
Ada Torres
19 Aug 2026
ReNerve Limited has gained marketing approval for its flagship NervAlign Nerve Cuff in India, marking a critical milestone in its global expansion and enabling commercial rollout in one of the world's largest nerve repair markets.
Ada Torres
Ada Torres
10 Aug 2026
ReNerve has secured marketing approval for its NervAlign® Nerve Cuff in the Philippines, tapping into a major Southeast Asian market with significant nerve injury demand.
Ada Torres
Ada Torres
6 Aug 2026
ReNerve Limited delivered its strongest sales quarter ever with $211,000 in revenue, boosted by new distribution deals in Asia-Pacific and a $5 million funding facility to underpin growth.
Ada Torres
Ada Torres
29 July 2026

Browse the archive

Full archive